Skip to content
NBDC Human Database

No datasets in the cart.

Go to the cart

Due to system maintenance, the application system, application review by the Data Access Committee will be unavailable during the following period.
Schedule: October 5th (Mon), 2026, 9:00 - October 7th (Wed), 2026, 15:00 (JST)
We apologize for any inconvenience this may cause and appreciate your understanding.

We are currently receiving a large number of applications for data submission, and the review process is taking longer than usual.We sincerely apologize for the delay and kindly ask for your understanding. When submitting an application, we would greatly appreciate it if you could allow sufficient time for the processing.

Following a change to our organizational structure effective April 1, 2026, this division has been renamed from the "Database Center for Life Science, Joint Support-Center for Data Science Research" to the "Database Division for Life Science (DBCLS), BioData Science Initiative (BSI), National Institute of Genetics (NIG)". Where the former name still appears in the guidelines, please read it as the new name.

Dataset ID

JGAD000954

Type of data
NGS (Target Capture)
Access criteria
Controlled-access (Type I)
Total data volume
68.8 GB
File formats
  • BAM
Research
hum0516
Date published
2026-05-21
Date modified
2026-05-21
DDBJ Search
JGAD000954 (opens in a new tab)
JGA Study
JGAS000812 (opens in a new tab)

Analysis method

Targeted DNA sequencing

Materials and participants
breast cancer (ICD10: C50.9): 127 cases
pBC 99 cases: 105 samples
mBC 34 cases: 45 samples
Details:
99 pBC patients, 99: before initial treatment, 6: plus after the neoadjuvant therapy.
34 mBC patients, at time point observed recurrence/distant metastasis (one; 25 samples, two; 7 samples and three; 2 samples).
Of these samples, 6 patients had samples with both pBC and mBC.
  • Health status
    Affected
  • Subject count
    127 (Mixed)
Disease
breast cancer (C509)
Sample description
cfDNA in blood
  • Tissue
    cfDNA, Peripheral blood
  • Tumor / normal
    Tumor
Sample provider
N/A
Experimental method
Targeted DNA sequencing
Target
26 genes (RERE, APH1A, AHNAK, SYTL2, CYP1A1, CLN3, ESRP2, DBNDD1, USP34, MFSD10, LRBA, BRD8, VPS28, KDM2A, SIDT2, ERBB2, TUBG2, CASP14, KYNU, ATIC, SLC12A5, CCDC50, SYNPO2, ESR1, SDK1, and AVL9)
Reagent kit
KAPA Hyper Prep Kit
xGen Duplex Seq Adapter-Tech Access
Fragmentation
N/A
Platform
Illumina NovaSeq 6000
Read type
Paired-end
Read length
100 bp
Reference genome
GRCh37
Mapping
Burrows-Wheeler aligner (BWA; version 0.5.9-r16)
Mapping quality
MAPQ filtering was not applied.
Coverage (depth)
200x
Processed data type
Alignment
Data use policy
NBDC data sharing policy (JGAP000001)